Form: S-3

Registration statement for specified transactions by certain issuers

February 3, 2025

Documents

 

EXHIBIT 107

 

Calculation of Filing Fee Tables

 

Form S-3

(Form Type)

 

FibroBiologics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1 - Newly Registered and Carry Forward Securities

 

    Security Type   Security Class Title   Fee Calculation or Carry Forward Rule   Amount Registered     Proposed Maximum Offering Price Per Unit     Maximum Aggregate Offering Price     Fee Rate     Amount of Registration Fee     Carry Forward Form Type     Carry Forward File Number     Carry Forward Initial Effective Date    

Filing Fee

Previously

Paid In

Connection

with

Unsold

Securities

to be

Carried

Forward

  
Newly Registered Securities
Fees to Be Paid   Equity   Common Stock, par value $0.00001 per share   457(o)     (2) (3)       (3)       (3)                                      
  Equity   Preferred Stock, par value $0.00001 per share   457(o)     (2) (3)       (3)       (3)                                                  
  Equity   Depositary Shares   457(o)     (2) (3)       (3)       (3)                                                  
  Other   Warrants   457(o)     (2) (3)       (3)       (3)                                                  
  Other   Subscription Rights   457(o)     (2) (3)       (3)       (3)                                                  
  Other   Contingent Value Rights   457(o)     (2) (3)       (3)       (3)                                                
  Debt   Debt Securities   457(o)     (2) (3)       (3)       (3)                                                  
  Other   Purchase Contracts   457(o)     (2) (3)       (3)       (3)                                                  
  Other   Units(1)   457(o)     (2) (3)       (3)       (3)                                                  
  Unallocated (Universal) Shelf   -   457(o)     (2) (3)       (3)     $ 50,000,000       $153.10 per $1,000,000     $ 7,655                                  
Fees Previously Paid   -   -   -     -       -       -               -                                  
Carry Forward Securities
Carry Forward Securities   -   -   -     -               -                       -       -       -       -  
    Total Offering Amounts               $   50,000,000             $ 7,655                                  
    Total Fees Previously Paid                                     -                                  
    Total Fee Offsets                                   $ 2,877.72                                  
    Net Fee Due                                   $ 4,777.28                                  

 

Table 2 – Fee Offset Claims and Sources

 

    Registrant or Filer Name   Form or Filing Type   File Number   Initial Filing Date   Filing Date   Fee Offset Claimed     Security Type Associated with Fee Offset Claimed     Security Title Associated with Fee Offset Claimed     Unsold Securities Associated with Fee Offset Claimed     Unsold Aggregate Offering Amount Associated with Fee Offset Claimed     Fee Paid with Fee Offset Source  
Rule 457(p)
Fee Offset Claims   FibroBiologics, Inc.   S-1   333-277019(4)   February 12, 2024   March 15, 2024   $ 2,877.72       Equity       Shares of Common Stock, par value $0.00001 per share, underlying warrants       1,299,783     $ 19,496,745       -  
Fees Offset Sources   FibroBiologics, Inc.   S-1   333-277019(4)   February 12, 2024   March 15, 2024     -       -       -       -       -     $ 2,877.72  

 

 

(1) Consisting of some or all of the securities listed above, in any combination.
   
(2) There is being registered hereunder an indeterminate (a) number of shares of common stock, (b) number of shares of preferred stock, (c) number of depositary shares to be evidenced by depositary receipts issued pursuant to a deposit agreement, (d) number of warrants that may represent the right to purchase shares of common stock, shares of preferred stock, depositary shares, contingent value rights or debt securities, (e) number of subscription rights that may represent a right to purchase shares of common stock, shares of preferred stock, depositary shares, contingent value rights or debt securities, (f) number of contingent value rights that represent a right to potential cash payment upon the satisfaction of one or more conditions set forth in a contingent value rights agreement, (g) principal amount of debt securities, (h) number of purchase contracts and (i) number of units that will be issued under a unit agreement and will represent an interest in a combination of one or more of the securities registered hereunder. If the registrant elects to offer to the public fractional interests in shares of preferred stock, then depositary receipts will be distributed to those persons purchasing the fractional interests and the shares of preferred stock will be issued to the depositary under the deposit agreement. The securities registered also include such indeterminate amount of securities as may be issued in exchange for, or upon conversion or exercise of, as the case may be, the preferred stock, depositary shares, warrants or subscription rights registered hereunder or pursuant to the antidilution provisions of any such securities. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. No separate consideration will be received for any securities registered hereunder that are issued in exchange for, or upon conversion of, as the case may be, the preferred stock, depositary shares, warrants or subscription rights. In no event will the aggregate offering price of all types of securities issued by the registrant pursuant to this registration statement exceed $50,000,000. If any debt securities are issued at an original issue discount, then the principal amount of such debt securities shall be in such greater amount as shall result in an aggregate initial offering price not to exceed $50,000,000, less the aggregate dollar amount of all securities previously issued hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers such indeterminate number of securities as may be issuable with respect to the securities being registered hereunder as a result of stock splits, stock dividends or similar transactions.
   
(3) The amount registered, the proposed maximum offering price per unit and the maximum aggregate offering price for each class of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and are not specified as to each class of security pursuant to Instructions 2.A.ii.b. and 2.A.iii.b. to the Calculation of Filing Fee Tables and Related Disclosure under Item 16(b) of Form S-3 under the Securities Act.
   
(4) On January 17, 2025, FibroBiologics, Inc. (the “Company”) filed a Post-Effective Amendment No. 1 to the registration statement on Form S-1 (File No. 333-277019) (the “S-1 Registration Statement”) to terminate the effectiveness of the S-1 Registration Statement and to remove from registration all securities registered but not sold under the S-1 Registration Statement. Pursuant to Rule 457(p) under the Securities Act, the Company is offsetting $2,877.72 of the fee previously paid by the Company in connection with the S-1 Registration Statement associated with unsold securities.